These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 12766322)
1. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Ramirez AD; Liu X; Menniti FS Neuroendocrinology; 2003 Apr; 77(4):223-31. PubMed ID: 12766322 [TBL] [Abstract][Full Text] [Related]
2. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Al-Sweidi S; Morissette M; Bourque M; Di Paolo T Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296 [TBL] [Abstract][Full Text] [Related]
4. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Grandbois M; Morissette M; Callier S; Di Paolo T Neuroreport; 2000 Feb; 11(2):343-6. PubMed ID: 10674483 [TBL] [Abstract][Full Text] [Related]
5. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368 [TBL] [Abstract][Full Text] [Related]
6. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Jourdain S; Morissette M; Morin N; Di Paolo T J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
8. Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Al-Sweidi S; Morissette M; Di Paolo T J Neuroendocrinol; 2012 Nov; 24(11):1375-85. PubMed ID: 22672467 [TBL] [Abstract][Full Text] [Related]
9. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. Bourque M; Dluzen DE; Di Paolo T Front Neuroendocrinol; 2012 Apr; 33(2):169-78. PubMed ID: 22387674 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW; Bradbury KA; Schneider JS Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease. Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817 [TBL] [Abstract][Full Text] [Related]
13. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. D'Astous M; Mendez P; Morissette M; Garcia-Segura LM; Di Paolo T Mol Pharmacol; 2006 Apr; 69(4):1492-8. PubMed ID: 16434614 [TBL] [Abstract][Full Text] [Related]
14. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Bourque M; Morissette M; Di Paolo T Neurobiol Aging; 2014 Oct; 35(10):2347-56. PubMed ID: 24726471 [TBL] [Abstract][Full Text] [Related]
15. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
18. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Xu K; Xu YH; Chen JF; Schwarzschild MA Neurosci Lett; 2002 Mar; 322(1):13-6. PubMed ID: 11958832 [TBL] [Abstract][Full Text] [Related]
19. Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Bourque M; Morissette M; Côté M; Soulet D; Di Paolo T Neurobiol Aging; 2013 Mar; 34(3):887-901. PubMed ID: 22749492 [TBL] [Abstract][Full Text] [Related]
20. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Xu K; Xu Y; Brown-Jermyn D; Chen JF; Ascherio A; Dluzen DE; Schwarzschild MA J Neurosci; 2006 Jan; 26(2):535-41. PubMed ID: 16407551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]